Spiropyrrolidine derived antiviral agents

Patent metadata

Field	Value
Publication number	US-11339170-B1
Application number	US-202117479455-A
Country	US
Kind code	B1
Filing date	Sep 20, 2021
Priority date	Jul 23, 2021
Publication date	May 24, 2022
Grant date	May 24, 2022

Abstract

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:

which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

First claim

What is claimed is:

1. A compound represented by Formula (XVI-A),

wherein
R 3a is hydrogen, methyl or CD 3 ;
R 1a is selected from the group consisting of

A is N(R 13a )(R 14a );
R 13a is hydrogen or CH 3 ; and
R 14a is C 1 -C 4 -alkyl, C 3 -C 6 -cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl.

2. The compound of claim 1 , wherein the compound is

3. The compound of claim 1 , wherein the compound is

4. The compound of claim 1 wherein the compound is

5. The compound of claim 1 , wherein the compound is

6. The compound of claim 1 , wherein the compound is

7. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

8. A pharmaceutical composition comprising the compound of claim 2 and a pharmaceutically acceptable carrier or excipient.

9. A pharmaceutical composition comprising the compound of claim 3 and a pharmaceutically acceptable carrier or excipient.

10. A pharmaceutical composition comprising the compound of claim 4 and a pharmaceutically acceptable carrier or excipient.

11. A pharmaceutical composition comprising the compound of claim 5 and a pharmaceutically acceptable carrier or excipient.

12. A pharmaceutical composition comprising the compound of claim 6 and a pharmaceutically acceptable carrier or excipient.

13. A method of treating or preventing a SARS-CoV-2 infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 1 .

14. A method of treating or preventing a SARS-CoV-2 infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 2 .

15. A method of treating or preventing a SARS-CoV-2 infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 3 .

16. A method of treating or preventing a SARS-CoV-2 infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 4 .

17. A method of treating or preventing a SARS-CoV-2 infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 5 .

18. A method of treating or preventing a SARS-CoV-2 infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 6 .

Assignees

• Enanta Pharm Inc

Inventors

• Gao Xuri
• Li Wei
• Zhang Jiajun
• Peng Xiaowen
• Cao Hui
• Kass Jorden
• Shen Ruichao
• Wang Guoqiang
• Or Yat Sun

Classifications

• C07D487/10 Primary

  Spiro-condensed systems · CPC title

• A61P31/14 Primary

  for RNA viruses · CPC title